Pulmonary Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Hypertension.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2011-03-02EMA Withdrawn: Thelin (sitaxentan sodium) — Pfizer Ltd.
Thelin (sitaxentan sodium) has been withdrawn from the market by Pfizer Ltd., with a status of Withdrawn in the EMA record.
-
EMA withdrawal · 2010-05-17EMA Application withdrawn: Tyvaso (treprostinil sodium) — United Therapeutics Europe Ltd
EMA reports that the application for Tyvaso (treprostinil sodium) by United Therapeutics Europe Ltd has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2010-03-16Clinical Trial Update: Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension [NA]
This clinical trial evaluating Type-5 phosphodiesterase inhibitors for primary and secondary pulmonary hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2009-07-30Clinical Trial Update: An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease [Phase 2]
This clinical trial update reports the termination of an open-label Phase 2 study evaluating PRX-08066 in patients with chronic obstructive …